Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
Executive Summary
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development
You may also be interested in...
Bristol pleads guilty in Plavix anti-trust case
Bristol-Myers Squibb agrees to plead guilty to criminal charges and pay as much as $1 million to settle a federal investigation of the firm's failed efforts to stave off market entry of Apotex's generic version of Plavix. The criminal charges stem from false statements made to the Federal Trade Commission by a former Bristol executive during the agency's antitrust review of an agreement between Bristol and Apotex, which received FDA approval for generic clopidogrel in January 2006. Bristol allegedly made verbal agreements with Apotex that were not included in written documents submitted to FTC (1"The Pink Sheet" March 27, 2006, p. 16). The plea is the culmination of a series of Plavix-related events that included to the ouster of Bristol's then-CEO, Peter Dolan...
Bristol pleads guilty in Plavix anti-trust case
Bristol-Myers Squibb agrees to plead guilty to criminal charges and pay as much as $1 million to settle a federal investigation of the firm's failed efforts to stave off market entry of Apotex's generic version of Plavix. The criminal charges stem from false statements made to the Federal Trade Commission by a former Bristol executive during the agency's antitrust review of an agreement between Bristol and Apotex, which received FDA approval for generic clopidogrel in January 2006. Bristol allegedly made verbal agreements with Apotex that were not included in written documents submitted to FTC (1"The Pink Sheet" March 27, 2006, p. 16). The plea is the culmination of a series of Plavix-related events that included to the ouster of Bristol's then-CEO, Peter Dolan...
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target